The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type

Mariia O. Yuneva, Teresa W.M. Fan, Thaddeus D. Allen, Richard M. Higashi, Dana V. Ferraris, Takashi Tsukamoto, José M. Matés, Francisco J. Alonso, Chunmei Wang, Youngho Seo, Xin Chen, J. Michael Bishop

Research output: Contribution to journalArticlepeer-review

385 Scopus citations


The altered metabolism of tumors has been considered a target for anticancer therapy. However, the relationship between distinct tumor-initiating lesions and anomalies of tumor metabolism in vivo has not been addressed. We report that MYC-induced mouse liver tumors significantly increase both glucose and glutamine catabolism, whereas MET-induced liver tumors use glucose to produce glutamine. Increased glutamine catabolism in MYC-induced liver tumors is associated with decreased levels of glutamine synthetase (Glul) and the switch from Gls2 to Gls1 glutaminase. In contrast to liver tumors, MYC-induced lung tumors display increased expression of both Glul and Gls1 and accumulate glutamine. We also show that inhibition of Gls1 kills cells that overexpress MYC and catabolize glutamine. Our results suggest that the metabolic profiles of tumors are likely to depend on both the genotype and tissue of origin and have implications regarding the design of therapies targeting tumor metabolism.

Original languageEnglish (US)
Pages (from-to)157-170
Number of pages14
JournalCell Metabolism
Issue number2
StatePublished - Feb 8 2012

ASJC Scopus subject areas

  • Physiology
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type'. Together they form a unique fingerprint.

Cite this